Sign In
Buy ALPMY
$13.40
-0.200 (-1.47%)
At Close: Jun 03, 2026
Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024
02:00am, Wednesday, 11'th Sep 2024
- Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs across a broad range of cancer types - TOKYO , Sept. 11,
Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
10:00am, Thursday, 05'th Sep 2024
The Astellas Life Sciences Center hosts the company's first U.S.-based open innovation SakuLab™ incubator space dedicated to fostering pioneering science through collaboration with external partners
Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
08:00am, Wednesday, 04'th Sep 2024
- Pooled analyses from two SKYLIGHT™ studies highlight impact on sleep disturbance and impairment, relationship between improvements in the frequency or severity of hot flashes and mood - Pooled da
- First regimen approved in advanced urothelial cancer to demonstrate superiority to platinum-containing chemotherapy, the standard of care for nearly 40 years1 - European Marketing Authorization bas
Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy
03:05am, Tuesday, 27'th Aug 2024
- HIGHLIGHT 1™ study to evaluate fezolinetant for treatment of moderate to severe vasomotor symptoms in women with stage 0-3 hormone receptor positive breast cancer receiving adjuvant endocrine ther
Japan's Astellas says employee indicted by China's prosecutors
06:59am, Wednesday, 21'st Aug 2024
Chinese authorities have indicted a Japanese employee of Astellas Pharma Inc , who had been detained in China since March 2023 on suspicion of espionage, the Japanese pharmaceutical company said on We
UK regulator approves Astellas' gastric cancer drug
07:08am, Wednesday, 14'th Aug 2024
Britain's health regulator said on Wednesday it has approved Astellas Pharma's drug to treat a type of gastric cancer.
Astellas Pharma Inc. (ALPMF) Q1 2024 Earnings Call Transcript
12:19pm, Saturday, 03'rd Aug 2024
Astellas Pharma Inc. (OTCPK:ALPMF) Q1 2024 Earnings Conference Call August 1, 2024 3:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and IRO Tadaaki Taniguchi - CMO Claus Zieler -
- If approved by the European Commission, zolbetuximab would become the first and only CLDN18.2-targeted therapy approved in the European Union - A decision on the EU marketi
- If approved, enfortumab vedotin in combination with pembrolizumab will be the first and only treatment to offer an alternative to platinum-containing chemotherapy, the current standard of care f
- Collaborative Research on Innovative Cartilage Organoid Cell Therapy for Intervertebral Disc Degenerative Disease using Astellas' Universal Donor Cell Technology - TOKYO and OSAKA, Japan , July 22,
U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE
10:30pm, Thursday, 30'th May 2024
If approved, the investigational therapy would offer a new treatment option for patients with advanced gastric and gastroesophageal junction cancers as the first and only CLDN18.2-targeted therapy in
Astellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor
11:39am, Wednesday, 08'th May 2024
- 154,000 square-foot lab and office facility creates a central location for Astellas' West Coast cell and gene therapy research and business development operations TOKYO and SAN FRANCISCO , May 8,
- Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors - TOKYO and SAN DIEGO , May 1, 2024 /PRNewswire/ -- Astellas Pharma
Astellas Pharma Inc. (ALPMF) Q4 2023 Earnings Call Transcript
06:00pm, Friday, 26'th Apr 2024
Astellas Pharma Inc. (OTCPK:ALPMF) Q4 2023 Results Conference Call April 25, 2024 4:00 AM ET Company Participants Hiromitsu Ikeda - Chief Communications and Investor Relations Officer Naoki Okamura -
